Alzheimer's Disease and Dementia
Our work in Alzheimer's Disease and Dementia
-
Association of Combination Statin and Antihypertensive Therapy With Reduced Alzheimer’s Disease and Related Dementia Risk
Drugs already being used to treat high blood pressure and cholesterol could reduce the risk of Alzheimer’s disease and dementia, according to a new Schaeffer Center study of nearly 700,000 Medicare beneficiaries.
Categorized in -
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
Research by Jakub Hlavka and colleagues suggests a combination of brief cognitive tests and blood-based biomarker tests will allow primary care physicians to identify patients with potential early stage Alzheimer’s disease efficiently and triage them for further evaluation.
Categorized in -
Supported by $2.33 Million National Institute on Aging Grant, Researchers Aim to Ensure Access to Future Alzheimer’s Treatments
Dana Goldman and Darius Lakdawalla are evaluating affordable ways to address the rising number of Alzheimer’s disease and related dementias patients, including developing novel reimbursement frameworks, to ensure these patients have access when an innovative treatment becomes available.
-
Are We Ready to Treat Alzheimer’s?
Alzheimer’s research has been associated with many more downs than ups, but with Biogen’s surprising decision to file for market authorization of aducanumab, the next major challenge is for national healthcare systems to get ready.
Categorized in -
Measuring Alzheimer’s Disease and Other Dementias in Diverse Populations Using Medicare Claims Data
The researchers examined how methods used for identifying dementia in administrative claims affected dementia incidence across racial/ethnic populations using a 100% sample of Medicare beneficiaries.
-
Longitudinal Analysis of Dementia Diagnosis and Specialty Care Among Racially Diverse Medicare Beneficiaries
The burden of Alzheimer’s disease and other dementias is rapidly growing. Researchers found vast majority of dementia patients don’t receive specialty diagnosis and care.
-
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment
A report on Canadian readiness to deal with new Alzheimer’s disease treatments co-authored by Jakub Hlávka found that average wait times could reach 28 months and that the most pressing issue is a lack of dementia specialists.
Categorized in -
Long-Term Pesticide Use and Risk of Dementia in the Agricultural Health Study of Memory in Aging
Pesticide use has been associated with increased risk of dementia in some, but not all studies; however, little is known about the long-term impact of specific pesticides on dementia risk.
Categorized in -
Analysis of Dementia in the U.S. Population Using Medicare Claims: Insights From Linked Survey and Administrative Claims Data
Insufficient understanding of the completeness of dementia diagnosis and for whom in Medicare claims data limits their use. This study analyzes prevalence and incidence of dementia in survey and claims data to understand differences.
-
Research Spotlight: Alzheimer’s Disease
Schaeffer Center researchers are analyzing trends associated with a greying population, including AD prevalence and cost, and what these trends mean for society.